ICCM Latest Press Releases

-- November 11, 2026 --

IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 PRNewswire 8:30 AM

-- November 9, 2026 --

IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio PRNewswire 8:25 AM

-- October 27, 2026 --

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation PRNewswire 8:33 AM

-- October 20, 2026 --

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites PRNewswire 7:55 AM

-- October 13, 2026 --

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026 PRNewswire 8:07 AM

-- October 6, 2026 --

IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site PRNewswire 8:26 AM

-- September 10, 2026 --

IceCure Medical Receives Regulatory Approval to Market ProSense in China PRNewswire 7:59 AM

-- August 24, 2026 --

IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands PRNewswire 7:50 AM

-- August 20, 2026 --

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation PRNewswire 8:11 AM

-- August 13, 2026 --

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation PRNewswire 9:11 AM

-- August 12, 2026 --

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year PRNewswire 8:30 AM

-- August 6, 2026 --

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment PRNewswire 8:05 AM

-- August 5, 2026 --

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026 PRNewswire 8:30 AM

-- July 29, 2026 --

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense PRNewswire 8:25 AM

-- July 27, 2026 --

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site PRNewswire 8:32 AM

-- July 14, 2026 --

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense Cryoablation PRNewswire 8:32 AM

-- July 6, 2026 --

IceCure Highlights Expanding Commercial Adoption of ProSense Cryoablation in Brazil Following FDA Clearance for Breast Cancer PRNewswire 8:12 AM

-- June 25, 2026 --

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement PRNewswire 8:12 AM

-- June 23, 2026 --

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer PRNewswire 8:10 AM

-- June 17, 2026 --

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor PRNewswire 1:15 PM

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers Globe Newswire 10:37 AM

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance PRNewswire 8:25 AM

Market Data Delayed 15 Minutes